Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Autologous Natural Killer Cell Therapy
- Development stage
- Unknown
- Lead developer
- Dr. Cipto Mangunkusumo Hospital
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
Autologous Natural Killer Cell Therapy is an adoptive cell therapy being developed by Dr Cipto Mangunkusumo General Hospital (RSCM) for the treatment of hepatocellular carcinoma (HCC). The treatment involves harvesting natural killer (NK) cells from the patient's own peripheral blood, which are then processed, expanded, and activated ex vivo using the CliniMACS Plus automated cell separation system and following Miltenyi Biotec guidelines. These activated NK cells are subsequently re-infused into the patient to target and eliminate malignant cells through innate immune mechanisms, such as the release of perforin and granzymes. The therapy is currently being evaluated in a Phase I clinical trial to determine safety, optimal dosage, and preliminary efficacy in patients with BCLC stage B or C hepatocellular carcinoma.
- Other names
- Autologous NK Cell TherapyAutologous Natural Killer Cell Therapy-Dr Cipto Mangunkusumo General Hospital-hepatocellular carcinoma
Beyond the preview
Go deeper on Autologous Natural Killer Cell Therapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Autologous Natural Killer Cell Therapy.